Objective: To evaluate trends in the clinical development of new pain and reformulated pain medications given the ongoing opioid crisis and the public health burden of inadequately controlled pain.
Methods: We conducted a retrospective cohort study of new drugs starting clinical testing between January 1, 2000, and December 31, 2015. We searched two comprehensive commercial databases of global research and development activity. The primary outcomes were trends in new and reformulated pain drugs starting clinical testing, proportion of new pain drugs targeting a novel biological pathway, and rates and reasons for discontinuation of development.
Results: The proportion of new pain drugs entering phase 1 testing (relative to all new drug trials) declined from 2.5% between 2000 and 2002 to 1.7% between 2013 and 2015. No significant changes in the proportion of new pain drugs entering phase 2 or phase 3 trials were observed. Most new pain drugs failed to reach late-stage clinical development, with 52% of pain drugs successfully advancing from phase 1 to phase 2 and 11% advancing from phase 2 to phase 3 trials. The number of reformulated products starting clinical testing increased over the study period and was greater than that for new analgesics in 2012 and every year thereafter.
Conclusion: Pain drug development activity has largely shifted from new therapeutics to reformulated ones. New policies, such as increased funding for basic pain research, may help address the urgent need for new therapies for pain.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Prescription of Controlled Substances: Benefits and RisksCV Preuss et al. PMID 30726003. - ReviewOne of the single most difficult challenges for any prescriber is to distinguish between the legitimate prescription of controlled substances versus the prescription pote …
Drug Discovery and Development for PainSR Chaplan et al. PMID 21882460. - ReviewTwo decades ago, systemic drugs indicated for pain belonged roughly to three mechanistic classes: the opioids, the nonselective NSAIDs, and the anticonvulsants, the latte …
Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) GuidelinesL Manchikanti et al. Pain Physician 20 (2S), S3-S92. PMID 28226332.The methodology utilized included the development of objectives and key questions. The methodology also utilized trustworthy standards, appropriate disclosures of conflic …
Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012TJ Hwang et al. JACC Basic Transl Sci 1 (5), 301-308. PMID 30167520. - ReviewCardiovascular disease remains a leading cause of death, but stakeholders have recently raised concerns about the pace of innovation and investment in developing new ther …
TuberculosisBR Bloom et al. PMID 30212088. - ReviewDespite 90 years of vaccination and 60 years of chemotherapy, tuberculosis (TB) remains the world’s leading cause of death from an infectious agent, exceeding human immun …